Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection

Recent successes with monoclonal antibody cocktails ZMapp

TM

 and MIL77 against Ebola virus (EBOV) infections have reignited interest in antibody-based therapeutics. Since the production process for monoclonal antibodies can be prolonged and costly, alternative treatments should be investigated.

Ebola virus (EBOV) is a pathogen from the Filoviridae family, and is capable of causing severe hemorrhagic fever in humans and non-human primates. Past outbreaks of EBOV disease (EVD) were sporadic, unpredictable and localized to remote regions of central Africa, with the death toll reaching up to 90%1. 

see more at: http://www.nature.com/articles/srep24179